96950 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans Cytokines; Lymphokines; Interferons
Reconstituted nipple skin model
#302METHODS FOR ENHANCING THE DELIVERY OF ACTIVE AGENTS
#303Inhibitors of type 2 vascular endothelial growth factor receptors
#304EPHA3 And multi-valent targeting of tumors
#305Human leucine zipper/trail recombinant polypeptides
#306Methods of administering an N-terminal modified PEG-TRAIL
#307Expression system for producing protein having a N-terminal pyroglutamate residue
#308Immunoconjugates
#309Chloroplast expressing colostrum or milk polypeptides
#310Tumor necrosis factor receptor soluble factor binding (TNFRSF-binding) agents
#311Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
#312Methods of preparing cysteine variants of human recombinant IL-11
#313Molecular signature of cancer
#314Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
#315Myonectin (CTRP15), compositions comprising same, and methods of use
#316GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES
#317Derivatisation of erythropoietin (EPO)
#318Derivatisation of erythropoietin (EPO)
#319MIC-1 fusion proteins and uses thereof
#320Derivatisation of granulocyte colony-stimulating factor
#321Inhibitors of the Eph-A receptor and uses thereof
#322Vaccines with biomolecular adjuvants
#323ZCYTOR17 heterodimeric cytokine receptor
#324THYMIC STROMAL LYMPHOPOIETIN FRAGMENTS AND USES THEREOF
#325Use of GPR83 to identify pruritus-related substances
#326Method of reducing blood glucose by administering RON agonists
#327MIC-1 fusion proteins and uses thereof
#328Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
#329Compositions and methods for modulating gamma-C-cytokine activity
#330Methods of diagnosing, treating and monitoring diabetic retinopathy
#331MACROPHAGE ACTIVATING FACTOR FOR PHARMACEUTICAL COMPOSITIONS
#332METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL STROMAL TUMOR (GIST)
#333Compositions and methods for expansion of embryonic hematopoietic stem cells
#334Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn
#335NON-VIRAL VECTOR
#336Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium
#337Derivatisation of granulocyte colony-stimulating factor
#338Modified Human Thymic Stromal Lymphopoietin
#339Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
#340Enhanced adoptive cell therapy
#341METHOD FOR PRODUCING MONOMERIC AND MULTIMERIC MOLECULES AND USES THEREOF
#342α/β-peptide mimics of Z-domain peptides
#343Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
#344Monoclonal antibody binding specifically to DLL4 and use thereof
#345Derivatisation of erythropoietin (EPO)
#346METHODS AND SYSTEMS FOR PROCESSING A CELL CULTURE
#347Use of SDF-1 to improve ischemic myocardial function
#348N-terminal derivatisation of proteins with polysaccharides
#349Methods for use of vascular endothelial growth factor antagonists
#350Cytokine-based fusion proteins for treatment of immune disorders
#351Therapeutic agents comprising fusions of growth hormone and elastic peptides
#352The IgM and IgE Heavy Chain Domain 2 as Covalently Linked Homodimerization Modules for the Generation of Fusion Proteins with Dual Specificity
#353Methods for treating hidradenitis suppurativa
#354Histamine-releasing factor (HRF), HRF-receptor and methods of modulating inflammation
#355Polynucleotides encoding ZCYTOR17 ligand antibodies
#356Antibodies that inhibit TSLP activity
#357OSTEOPONTIN ISOFORM A INHIBITORS AND METHODS OF USE
#358Alpha-1 antitrypsin variant, preparation method thereof and use thereof
#359Myonectin (CTRP15), compositions comprising same, and methods of use
#360Method for obtaining a dialyzable leukocyte extract
#361Fusion protein comprising circularly permuted form of trail/Apo2L, coding gene and use thereof
#362Vascular endothelial growth factor 2
#363Compounds modulators of VEGF activity and uses thereof
#364Activated collagen scaffold materials and their special fused active restoration factors
#365Activated collagen scaffold materials and their special fused active restoration factors
#366Derivatisation of erythropoietin (EPO)
#367Derivatisation of erythropoietin (EPO)
#368VEGF analogs
#369Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
#370Suppression of cancer
#371Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use
#372KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#373Methods for making cytokine compositions from tissues using non-centrifugal methods
#374Methods for making cytokine compositions from tissues using non-centrifugal methods
#375Compositions for treating glioma
#376Fusion protein for suppressing cancer cell growth and suppressing vasculogenesis, and anticancer composition comprising same
#377Therapeutic agents comprising fusions of insulin and elastic peptides
#378Therapeutic TRAIL fusion protein and preparation and use thereof
#379Targeting vector-phospholipid conjugates
#380Multimeric constructs
#381Inhibitors of type 2 vascular endothelial growth factor receptors
#382Method of inhibiting binding or activity of MIF by administering a MIF antagonist
#383CARDIOTROPHIN RELATED MOLECULES FOR ENHANCED THERAPEUTICS
#384USE OF CARDIOTROPHIN-1 FOR THE TREATMENT OF KIDNEY DISEASES
#385DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
#386Derivatisation of granulocyte colony-stimulating factor
#387KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#388Compositions and methods for modulating gamma-c-cytokine activity
#389SELECTIVE BINDING AGENTS OF OSTEOPROTEGERIN BINDING PROTEIN
#390ZCYTOR17 heterodimeric cytokine receptor
#391N-terminal derivatisation of proteins with polysaccharides
#392KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#393Nucleic acids encoding modified human thymic stromal lymphopoietin
#394VEGF-D/VEGFR2/3-mediated regulation of dendrites
#395Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
#396Method for isolating osteopontin using concentrated feeds
#397Method for isolating osteopontin using feeds containing CMP or casein species
#398Biological active proteins having increased in vivo and/or in vitro stability
#399Targeting vector-phospholipid conjugates
#400ANTICANCER FUSION PROTEIN
#401Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
#402Protein-binding peptide isolated from placenta growth factor
#403Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
#404Moesin fragments associated with immune thrombocytopenia
#405Anticancer fusion protein comprising trail and a growth factor receptor inhibitor
#406Humanized transgenic animal
#407Antibodies That Inhibit TSLP Activity
#408Recombinant production of vascular endothelial growth factor
#409Compositions and methods for modulating γ-c-cytokine activity
#410Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
#411Peptide having the ability to regenerate bone tissue and for binding to apatite
#412Moesin fragments and uses thereof
#413Cerberus/Coco derivatives and uses thereof
#414Moesin fragments associated with aplastic anemia
#415Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells
#416Growth factor isoform
#417Angiogenesis-inhibiting peptide and application thereof
#418APO-2 LIGAND/TRAIL VARIANTS AND USES THEREOF
#419Anticancer fusion protein comprising trail
#420Methods of decorating hydroxyapatite biomaterials with modular biologically active molecules
#421Molecular signature of cancer
#422FROG/TOAD conditionally silenced vectors for hypoxia gene therapy
#423Derivatisation of erythropoietin (EPO)
#424Process for the purification of a growth factor protein
#425RECOMBINANT PRODUCTION OF AUTHENTIC HUMAN PROTEINS USING HUMAN CELL EXPRESSION SYSTEMS
#426METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS
#427METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS
#428Antagonists of ligands and uses thereof
#429INDUCTIVE PRODUCTION OF PLURIPOTENT STEM CELLS USING SYNTHETIC TRANSCRIPTION FACTORS
#430Modified human thymic stromal lymphopoietin
#431Method of treating fibroproliferative disorders of the heart and lung
#432Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
#433THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES
#434Nucleic acids encoding GAS57 mutant antigens
#435Compositions and methods for modulating γ-c-cytokine activity
#436Methods of making VEGF-D polypeptides
#437Antibody fusion with IL-12 proteins with disrupted heparin-binding activity
#438Production of Therapeutic Proteins in Photosynthetic Organisms
#439VEGF-D/VEGFR2/3-MEDIATED REGULATION OF DENDRITES
#440Regulation of endogenous gene expression in cells using zinc finger proteins
#441Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides
#442Immunoconjugates
#443Method of enhancing the acceptance and/or healing of a skin graft
#444ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR POLYNUCLEOTIDES
#445CYTOKINE-LIKE PROTEINS
#446Detection of B-cell activating factor as a biomarker for antibody mediated rejection in transplant recipients
#447Proteolysis Resistant Active VEGF
#448INTERFERON-LIKE PROTEIN ZCYTO21
#449IMMUNOTHERAPY
#450Therapeutic agents comprising pro-apoptotic proteins
#451Antimicrobial activity of chicken NK-2 peptide against apicomplexan protozoa
#452Method for producing proteins in that lack detectable cross binding activity to antibodies against host cell antigens
#453Methods of treatment using cysteine variants of interleukin-11
#454Truncated cystine-knot proteins
#455VEGF-RELATED PROTEIN
#456DIAGNOSTIC METHOD FOR DETECTING CANCER BY MEASURING AMOUNT OF A CYTOKINE LIKE IL-6
#457Polypeptides and nucleic acids for treating ErbB2-dependent cancers
#458METHODS OF TARGETING BAFF
#459VASCULAR ENDOTHELIAL GROWTH FACTOR 2
#460Cytokine zalpha11 ligand
#461Antibody to human zcyto-10 polypeptide
#462Compositions and Methods for Modulation of Bone Density and Biomineralization
#463Receptor activator of NF-kappaB
#464T CELL PROTEINS AND NUCLEOTIDES ENCODING THE SAME
#465Apo-2 LIGAND/TRAIL VARIANTS AND USES THEREOF
#466INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY
#467Method of screening a substance for improving insulin resistance
#468Compositions and methods for the diagnosis and treatment of immune disorders
#469Modified human interferon polypeptides and their uses
#470IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
#471Recombinant Human Albumin-Granulocyte Macrophage Colony Stimulating Factor Fusion Protein With Long-Lasting Biological Effects
#472Chimeric VEGF Peptides
#473Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
#474Antibodies that immunospecifically bind to B lymphocyte stimulator protein
#475Compounds modulators of VEGF activity and uses thereof
#476MODIFIED VEGF-A WITH IMPROVED ANGIOGENIC PROPERTIES
#477METHOD OF MASS PRODUCING GROWTH FACTOR USING ADIPOSE DERIVED ADULT STEM CELLS
#478B LYMPHOCYTE STIMULATOR ASSAYS
#479MIF antagonists
#480Methods of treatment using antibodies to Neutrokine-alpha
#481INTERFERON-LIKE PROTEIN ZCYTO21
#482Cells and methods for producing blocking antibodies to human RANKL
#483INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY
#484GROWTH FACTOR HOMOLOG ZVEGF4
#485Antibodies specifically binding to human TSLPR and methods of use
#486VEGF antibodies comprising modular recognition domains
#487Multispecific antibody targeting and multivalency through modular recognition domains
#488Antibodies that inhibit TSLP activity
#489NOVEL USES OF VEGFXXXB
#490Novel Retinoid Inducible Factor and Uses Thereof
#491Polypeptides Homologous to VEGF and BMP1
#492CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#493PROSAPOSIN AS A NEUROTROPHIC FACTOR
#494TRAIL trimers, methods and uses therefor
#495ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN
#496VEGF-LIKE FACTOR ANTIBODIES AND METHODS OF USE THEREOF
#497Use of VEGF and homologues to treat neuron disorders
#498Method of treatment using organotypically cultured skin tissue comprising NIKS cells that express exogenous HIF-1α
#499TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
#500Methods of stimulating wound healing by administration of vascular endothelial growth factor D (VEGF-D)
#501Cell penetrating peptides for intracellular delivery
#502Methods and compositions for targeting agents into and across the blood-brain barrier and other endothelial cell microvascular barriers
#503PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
#504PROTEOGLYCAN-BINDING PEPTIDES THAT MODULATE STEM CELL BEHAVIOR
#505Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas
#506Multimeric constructs
#507SUPPRESSION OF CANCER
#508LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors
#509Cysteine variants of interferon gamma
#510Regulation of endogenous gene expression in cells using zinc finger proteins
#511IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES
#512MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
#513Vascular endothelial growth factor 2
#514Chemokine containing apheresis column and methods of use
#515Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
#516USE OF MICROPARTICLES CONTAINING GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
#517PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS
#518Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
#519EXPRESSION OF IMMUNOGLOBULIN-CYTOKINE FUSION PROTEINS IN MALIGNANT B CELLS
#520Kits for detecting rank
#521Murine zcytor17 ligand polynucleotides
#522PROSAPOSIN AS A NEUROTROPHIC FACTOR
#523Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins
#524Set of Antiangiogenic Molecules and Use Thereof
#525INTERFERON-LIKE PROTEIN ZCYTO21
#526Method of preparing cysteine mutants of human recombinant GM-CSF
#527NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
#528VEGF-D mutants and their use
#529Protease resistant modified IFN beta polypeptides and their use in treating diseases
#530Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
#531B LYMPHOCYTE STIMULATOR ASSAYS
#532Decorating hydroxyapatite biomaterials with modular biologically active molecules
#533Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
#534Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
#535PHOSPHOPEPTIDES AND USE OF THE SAME
#536ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN
#537GAS57 mutant antigens and GAS57 antibodies
#538INSULIN RESISTANCE MARKER
#539KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#540SIRNA OF HUMAN OSTEOPONTIN
#541Cytokine-Like Proteins
#542OX40R Binding Agents
#543Method of inhibiting osteoclast activity
#544Antibody to human Zcyto10 polypeptide
#545Methods of identifying compounds that bind TANGO240
#546Chimeric antigen-specific T cell-activating polypeptides
#547EXPRESSION VECTORS AND CELL LINES EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D, AND METHOD OF TREATING MELANOMAS
#548Method of treatment using organotypically cultured skin tissue comprising niks cells that express exogenous HIF-1a
#549Antibodies to interferon-like protein Zcyto21(IL29)
#550Recombinant production of authentic human proteins using human cell expression systems
#551NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF
#552METHOD OF TREATING HEPATOCELLULAR CARCINOMA
#553Therapeutic agent for diabetes
#554Methods of treatment using antibodies to IL-17 homologous polypeptides
#555Stabilisation of Proteins
#556CITRULLINATED CYTOKINES
#557Method of inhibiting binding or activity of MIF by administering a MIF antagonist
#558Hypoxia inducible VEGF plasmid for ischemic disease
#559Use of proteolysis resistant active VEGF
#560Therapeutic agents comprising pro-apoptotic proteins
#561STEM CELLS FOR USE IN LOCATING AND TARGETING TUMOR CELLS
#562POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
#563METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES
#564METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA
#565Nucleic acid encoding 10FN3 polypeptide inhibitors of Type 2 vascular endothelial growth factor receptors
#566COMPOSITIONS COMPRISING MODULATORS OF SIGNAL TRANSDUCING RECEPTOR gp130 AND METHODS OF PRODUCING AND USING SAME
#567Growth factor isoform
#568Cytokine zalpha11 ligand antibodies
#569CYTOKINE ZALPHA11 LIGAND ANTIBODIES
#570Biological active proteins having increased in vivo and/or in vitro stability
#571Eta-1 gene and methods for use
#572Method of treating fibrproliferative disorders
#573Compositions and methods for tissue repair
#574VEGF VARIANTS
#575Pharmaceutical and/or cosmetic composition containing active-principle activators of aconitase
#576Platelet promoting protein and the usage thereof
#577Alteration of tumor growth using zinc finger proteins
#578Integrated cytokine production system
#579Modified polypeptides suitable for acceptace of amino acid substited molecules
#580Chimeric nucleic acids encoding polypeptides comprising CD70 and Fas ligand domains
#581ANTIBODIES THAT INHIBIT TSLP ACTIVITY
#582Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells
#583CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#584CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#585Recombinant Production of Heparin Binding Proteins
#586Regulation of endogenous gene expression in cells using zinc finger proteins
#587NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF
#588EG-VEGF nucleic acids and polypeptides and methods of use
#589EG-VEGF nucleic acids and polypeptides and methods of use
#590THE FUNCTIONAL EPITOPE OF OSTEOPONTIN, THE ANTI-OSTEOPONTIN MONOCLONAL ANTIBODY AND USE THEREOF
#591IMMUNOGENIC EPITOPES, PEPTIDOMIMETICS, AND ANTI-PEPTIDE ANTIBODIES, AND METHODS OF THEIR USE
#592Targeting vector-phospholipid conjugates
#593Cytokine zalpha11 ligand antibodies
#594Method of using interferon-like protein ZCYTO21(IL-29) to treat hepatitis B
#595VEGF superagonists and methods of use
#596Process for isolation and purification of a target protein free of prion protein (PrP)
#597Nucleic acids encoding murine IL-174
#598Use of SDF-1 to improve ischemic myocardial function
#599NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
#600Viral particles encoding multifunctional cytokines